Bluebird: CAR T cell therapy approval puts us on the road to broader oncology success
The FDA’s recent endorsement of Abecma marks the first approved treatment in oncology for gene therapy developer, bluebird bio.
Archives for April 1, 2021
Ajinomoto and Bright Peak partner to develop immunocytokines
Ajinomoto Co., Inc, and Bright Peak Therapeutics Inc. have entered into a research collaboration and license agreement to develop immunocytokines.